United Therapeutics Corporation (UTHR) P/E Ratio History
Premium ValuationTrading at 20.2x vs 5Y avg 15.3x · 90th percentile · Premium to historical baseline · Data 2004–2026
Loading P/E history...
P/E Ratio Analysis
As of July 8, 2026, United Therapeutics Corporation (UTHR) trades at a price-to-earnings ratio of 20.2x, with a stock price of $563.70 and trailing twelve-month earnings per share of $27.28.
The current P/E is 32% above its 5-year average of 15.3x. Over the past five years, UTHR's P/E has ranged from a low of 10.9x to a high of 21.9x, placing the current valuation at the 90th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.4x, UTHR is roughly in line with its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 198.8x.
The PEG ratio of 1.05 (P/E divided by 13% EPS growth) suggests a fair valuation relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.
Relative to the broader market, UTHR trades at a notable discount to the S&P 500 median P/E of 25.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our UTHR DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
UTHR Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
UTHR P/E vs Peers
Commercial Specialty Pharma peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $4B | 11.4 | - | +68% | |
| $2B | 6.7Lowest | 0.65Best | +817% | |
| $10B | 31.9 | 1.39 | -25% | |
| $1B | 211.0 | - | -79% | |
| $7B | 30.3 | - | -22% | |
| $6B | 52.1 | - | +2886%Best |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
UTHR Historical P/E Data (2004–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $592.87 | $27.05 | 21.9x | -19% |
| FY2025 Q4 | Dec 31 2025 | $487.25 | $27.86 | 17.5x | -35% |
| FY2025 Q3 | - | $419.21 | $26.39 | 15.9x | -41% |
| FY2025 Q2 | Jun 30 2025 | $287.35 | $25.62 | 11.2x | -58% |
| FY2025 Q1 | Mar 31 2025 | $308.27 | $25.06 | 12.3x | -54% |
| FY2024 Q4 | - | $352.84 | $24.60 | 14.3x | -47% |
| FY2024 Q3 | Sep 30 2024 | $358.35 | $22.77 | 15.7x | -41% |
| FY2024 Q2 | Jun 30 2024 | $318.55 | $21.76 | 14.6x | -46% |
| FY2024 Q1 | Mar 31 2024 | $229.72 | $21.15 | 10.9x | -60% |
| FY2023 Q4 | Dec 31 2023 | $219.89 | $19.84 | 11.1x | -59% |
| FY2023 Q3 | Sep 30 2023 | $225.87 | $18.15 | 12.4x | -54% |
| FY2023 Q2 | Jun 30 2023 | $220.75 | $17.68 | 12.5x | -54% |
| FY2023 Q1 | Mar 31 2023 | $223.96 | $14.85 | 15.1x | -44% |
| FY2022 Q4 | Dec 31 2022 | $278.09 | $15.02 | 18.5x | -31% |
| FY2022 Q3 | Sep 30 2022 | $209.38 | $14.70 | 14.2x | -47% |
| FY2022 Q2 | - | $235.64 | $13.21 | 17.8x | -34% |
| FY2022 Q1 | - | $179.41 | $14.45 | 12.4x | -54% |
| FY2021 Q4 | Dec 31 2021 | $216.08 | $10.03 | 21.5x | -20% |
| FY2021 Q3 | - | $184.58 | $9.87 | 18.7x | -30% |
| FY2021 Q2 | Jun 30 2021 | $179.41 | $10.29 | 17.4x | -35% |
| FY2021 Q1 | Mar 31 2021 | $167.27 | $9.05 | 18.5x | -31% |
| FY2020 Q4 | - | $151.79 | $11.56 | 13.1x | -51% |
| FY2020 Q3 | Sep 30 2020 | $101.00 | $10.57 | 9.6x | -64% |
| FY2020 Q2 | - | $121.00 | $9.74 | 12.4x | -54% |
| FY2020 Q1 | - | $94.83 | $11.99 | 7.9x | -71% |
| FY2018 Q4 | Dec 31 2018 | $108.90 | $13.45 | 8.1x | -70% |
| FY2018 Q3 | Sep 30 2018 | $127.88 | $12.40 | 10.3x | -62% |
| FY2018 Q2 | Jun 30 2018 | $113.15 | $16.25 | 7.0x | -74% |
| FY2018 Q1 | Mar 31 2018 | $112.36 | $11.02 | 10.2x | -62% |
| FY2017 Q4 | Dec 31 2017 | $147.95 | $9.34 | 15.8x | -41% |
| FY2017 Q3 | Sep 30 2017 | $117.19 | $11.34 | 10.3x | -62% |
| FY2017 Q2 | Jun 30 2017 | $129.73 | $8.57 | 15.1x | -44% |
| FY2017 Q1 | Mar 31 2017 | $135.38 | $14.21 | 9.5x | -65% |
| FY2016 Q4 | Dec 31 2016 | $143.43 | $15.16 | 9.5x | -65% |
| FY2016 Q3 | Sep 30 2016 | $118.08 | $14.83 | 8.0x | -70% |
| FY2016 Q2 | - | $105.92 | $20.57 | 5.1x | -81% |
| FY2016 Q1 | - | $111.43 | $18.09 | 6.2x | -77% |
| FY2015 Q4 | - | $156.61 | $12.89 | 12.1x | -55% |
| FY2015 Q3 | Sep 30 2015 | $131.24 | $12.96 | 10.1x | -62% |
| FY2015 Q2 | - | $173.95 | $3.19 | 54.5x | +103% |
| FY2015 Q1 | - | $172.44 | $3.38 | 51.0x | +90% |
| FY2014 Q4 | Dec 31 2014 | $129.49 | $6.17 | 21.0x | -22% |
| FY2014 Q3 | - | $128.65 | $3.40 | 37.8x | +41% |
| FY2014 Q2 | Jun 30 2014 | $88.49 | $5.10 | 17.4x | -35% |
| FY2014 Q1 | Mar 31 2014 | $94.03 | $4.52 | 20.8x | -23% |
| FY2013 Q4 | - | $113.08 | $3.28 | 34.5x | +28% |
| FY2013 Q3 | Sep 30 2013 | $78.85 | $5.47 | 14.4x | -46% |
| FY2013 Q2 | Jun 30 2013 | $65.82 | $5.76 | 11.4x | -58% |
| FY2013 Q1 | Mar 31 2013 | $60.87 | $5.58 | 10.9x | -59% |
| FY2012 Q4 | Dec 31 2012 | $53.42 | $5.68 | 9.4x | -65% |
| FY2012 Q3 | Sep 30 2012 | $55.88 | $4.88 | 11.5x | -57% |
| FY2012 Q2 | Jun 30 2012 | $49.38 | $4.80 | 10.3x | -62% |
| FY2012 Q1 | Mar 31 2012 | $47.13 | $4.64 | 10.2x | -62% |
| FY2011 Q4 | Dec 31 2011 | $47.25 | $3.61 | 13.1x | -51% |
| FY2011 Q3 | Sep 30 2011 | $37.49 | $2.97 | 12.6x | -53% |
| FY2011 Q2 | - | $55.10 | $2.25 | 24.5x | -9% |
| FY2011 Q1 | - | $67.02 | $1.69 | 39.7x | +47% |
| FY2010 Q4 | Dec 31 2010 | $63.22 | $1.75 | 36.1x | +34% |
| FY2010 Q3 | - | $56.01 | $1.54 | 36.3x | +35% |
| FY2010 Q2 | Jun 30 2010 | $48.81 | $1.09 | 44.6x | +66% |
| FY2010 Q1 | Mar 31 2010 | $55.33 | $0.43 | 128.6x | +378% |
| FY2009 Q4 | - | $52.65 | $0.35 | 150.3x | +459% |
| FY2008 Q3 | - | $52.59 | $0.80 | 65.6x | +144% |
| FY2008 Q2 | Jun 30 2008 | $48.88 | $0.91 | 53.6x | +99% |
| FY2008 Q1 | Mar 31 2008 | $43.35 | $0.74 | 58.5x | +118% |
| FY2007 Q4 | Dec 31 2007 | $48.83 | $0.44 | 112.1x | +317% |
| FY2007 Q3 | Sep 30 2007 | $33.27 | $1.69 | 19.6x | -27% |
| FY2007 Q2 | Jun 30 2007 | $31.88 | $1.53 | 20.8x | -23% |
| FY2007 Q1 | Mar 31 2007 | $26.89 | $1.55 | 17.3x | -36% |
| FY2006 Q4 | Dec 31 2006 | $27.18 | $1.67 | 16.3x | -39% |
| FY2006 Q3 | Sep 30 2006 | $26.31 | $0.94 | 28.1x | +5% |
| FY2006 Q2 | Jun 30 2006 | $28.89 | $1.07 | 26.9x | -0% |
| FY2006 Q1 | Mar 31 2006 | $33.14 | $1.18 | 28.2x | +5% |
| FY2005 Q4 | Dec 31 2005 | $34.56 | $1.29 | 26.8x | -0% |
| FY2005 Q3 | Sep 30 2005 | $34.90 | $0.86 | 40.6x | +51% |
| FY2005 Q2 | - | $24.10 | $0.69 | 34.9x | +30% |
| FY2005 Q1 | - | $22.85 | $0.53 | 43.1x | +60% |
| FY2004 Q4 | Dec 31 2004 | $22.57 | $0.33 | 69.1x | +157% |
| FY2004 Q3 | - | $17.46 | $0.11 | 157.1x | +484% |
Average P/E for displayed period: 26.9x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
22+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
UTHR — Frequently Asked Questions
Quick answers to the most common questions about buying UTHR stock.
What is UTHR's P/E ratio?
United Therapeutics Corporation (UTHR) trailing twelve-month P/E ratio is 20.2x, based on TTM diluted EPS of $27.28. The 5-year average P/E is 15.3x and the historical range spans 10.9x to 21.9x.
Is UTHR stock overvalued or undervalued?
UTHR trades at 20.2x P/E, above its 5-year average of 15.3x. The 90th percentile ranking within the 10.9x–21.9x historical range indicates a premium to historical valuation.
Is UTHR stock expensive?
Yes, UTHR is expensive relative to its own history. The current P/E of 20.2x is above the 5-year average of 15.3x. The stock sits at the 90th percentile of its 5-year valuation range.
What is UTHR's historical P/E range?
Over the past 5 years, UTHR's P/E ratio has ranged from 10.9x to 21.9x, with a median of 15.1x and an average of 15.3x. The current P/E of 20.2x places the stock at the 90th percentile of this range. Full historical data spans 2004–2026.
How does UTHR's P/E compare to the S&P 500?
UTHR trades at 20.2x P/E versus the S&P 500 median of 25.9x. The 22% discount to the market suggests lower growth expectations or perceived higher risk.
How does UTHR's valuation compare to Healthcare peers?
United Therapeutics Corporation P/E of 20.2x compares to the Healthcare sector median of 23.4x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is UTHR's PEG ratio?
UTHR PEG ratio is 1.05, based on a P/E of 20.2x and EPS growth of 13.1%. A PEG between 1 and 2 suggests valuation aligns with growth expectations — typically considered fair.
What is UTHR's earnings yield?
UTHR earnings yield is 4.94%, the inverse of its 20.2x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.